Clinical Research Directory

Inclusion Criteria: 1. Must freely sign informed consent; 2. Aged 18 to 80 years old; 3. Histologically or cytologically confirmed diagnosis of esophagus cancer; 4. ECOG score is 0 or 1; 5. completed Neoadjuvant combined with PD-1 therapy ;Completed surgical resection ;At the same time, standard postoperative treatment was performed 8 \~ 12 weeks of therapy; 6. Must provide all exons of tumor tissue sequencing data, transcriptome sequencing data and the peripheral blood of all exons sequencing data; 7. Completion of imaging records 1 week before personalized immunotherapy, including but not limited to full-body PET-CT and brain MRI, 8. Haematological index： White blood cells ≥ 3500 / MCL; Lymphocytes \> 800/ MCL; neutrophils \> 1500/ MCL; Platelets \> 100000 / MCL; Hemoglobin \>10.0g/dL; Total serum bilirubin \<1.5× upper limit of normal value (ULN); AST/ALT\<2.0 times the upper limit of normal; Serum creatinine \<1.5 times the upper limit of normal； 9. Pregnant, lactating women and women of child-bearing age must have a negative pregnancy test within 7 days before entering the group, and short-term have no fertility plan, and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial; 10. Male patients are willing to take appropriate methods of contraception; 11. Good compliance, able to follow research protocols and follow-up procedures; Exclusion Criteria: 1. Diagnosed as other malignant tumor; 2. No neoantigen was found in the sequencing data; 3. Patients are unable to tolerate surgery and adjuvant therapy or patients with poor immune system status; 4. There have been bone marrow or stem cell transplants; 5. Received other systemic antitumor agents or systemic glucocorticoids with immunosuppressants; 6. Received other vaccine inoculation 4 weeks before treatment; 7. With HIV, HCV, HBV infection, severe asthma, autoimmune disease,immunodeficiency or treated with immunosuppressive drugs; 8. Uncontrolled complications include, but are not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, and arrhythmias; 9. Infected with herpes virus (except those with scabs of more than 4 weeks); 10. Infected with respiratory virus (except those who have recovered for more than 4 weeks); 11. Have severe coronary or cerebrovascular disease, or other conditions considered ineligible by the investigator; 12. Drug abuse. Clinical, psychological or social factor result in affecting informed consent or research implementation; 13. Have a history of drug or vaccine allergies, or people who are allergic to other potential immunotherapies;